Peripheral stem cell mobilization and engraftment in patients over age 60.
Data from 225 multiple myeloma (MM) patients, undergoing peripheral stem cell (PBSC) mobilization with high-dose cyclophosphamide and hematopoietic growth factors, were analyzed for median CD34+ cell count and median time to post-transplant neutrophil (ANC > 500/microliters) and platelet (> 50,000/microliters) recovery according to age groups (20-49, 50-59 and > or = 60 years) and duration of prior therapy (< or = 12, 13-24, or > 24 months). Fifty-seven of the 225 patients were > or = 60 years. No difference in either the median number of CD34+ cells collected or time to engraftment occurred between age groups, when adjusted for duration of prior therapy. These data support the concept that autotransplants can be performed safely in patients > or = 60 years and that these patients should not be excluded from the most effective treatment modalities.
Guba
S C
SC
Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA.
Vesole
D H
DH
Jagannath
S
S
Bracy
D
D
Barlogie
B
B
Tricot
G
G
D000328:Adult; D000367:Age Factors; D000368:Aged; D002469:Cell Separation; D003520:Cyclophosphamide; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D019089:Stem Cell Factor
D019089:Stem Cell Factor; D003520:Cyclophosphamide